KRAS and neoplasm: The potential use of let-7 as a chemo-sensitizer has also emerged in KRAS mutant NSCLC cells, in which let-7b repletion selectively sensitized KRAS mutant tumor cells to paclitaxel and gemcitabine by diminishing MEK/ERK and PI3K/AKT signaling [142].